Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe Sells 57,606 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 57,606 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the transaction, the senior vice president now owns 4,841 shares in the company, valued at $214,698.35. This trade represents a 92.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jolanda Howe also recently made the following trade(s):

• On Monday, February 3rd, Jolanda Howe sold 1,064 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $48.22, for a total value of $51,306.08.
• On Friday, January 24th, Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total value of $43,223.84.
• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $32,115.00.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM opened at $44.31 on Wednesday. The business has a 50 day moving average price of $47.55 and a 200 day moving average price of $43.60. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $54.23. The company has a market cap of $2.17 billion, a price-to-earnings ratio of -21.94 and a beta of 1.04. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $99.41 million for the quarter, compared to the consensus estimate of $96.64 million. Research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Robert W. Baird upped their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research note on Thursday, February 27th. HC Wainwright upped their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $58.20.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at approximately $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Mirum Pharmaceuticals by 16.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 73,888 shares of the company’s stock valued at $3,055,000 after acquiring an additional 10,427 shares in the last quarter. Woodline Partners LP raised its holdings in Mirum Pharmaceuticals by 22.2% in the 4th quarter. Woodline Partners LP now owns 404,404 shares of the company’s stock valued at $16,722,000 after acquiring an additional 73,399 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at approximately $897,000. Finally, Tema Etfs LLC acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at approximately $1,735,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.